Tamoxifen Protects from Vesicular Stomatitis Virus Infection.
antiviral activity
interferon
tamoxifen (TAM)
vesicular stomatitis virus (VSV) infection
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
20 Sep 2019
20 Sep 2019
Historique:
received:
07
08
2019
revised:
30
08
2019
accepted:
17
09
2019
entrez:
25
9
2019
pubmed:
25
9
2019
medline:
25
9
2019
Statut:
epublish
Résumé
Tamoxifen (TAM) is an estrogen-receptor antagonist, widely used in the adjuvant treatment of early stage estrogen-sensitive breast cancer. Several studies have revealed new biological targets of TAM that mediate the estrogen receptor independent activities of the drug. Recently, the antiviral activity of TAM on replication of human immunodeficiency virus (HIV), hepatitis C virus (HCV) and Herpes simplex virus (HSV-1) in vitro was described. In the current study, we aimed to investigate the effect of TAM on infection with vesicular stomatitis virus (VSV). Vero cells were treated with different concentrations of TAM for 24 h and then infected with VSV. Additionally, C57BL/6 mice were pretreated with 4 mg TAM, one day and three days before infection with VSV.
Sections du résumé
BACKGROUND
BACKGROUND
Tamoxifen (TAM) is an estrogen-receptor antagonist, widely used in the adjuvant treatment of early stage estrogen-sensitive breast cancer. Several studies have revealed new biological targets of TAM that mediate the estrogen receptor independent activities of the drug. Recently, the antiviral activity of TAM on replication of human immunodeficiency virus (HIV), hepatitis C virus (HCV) and Herpes simplex virus (HSV-1) in vitro was described. In the current study, we aimed to investigate the effect of TAM on infection with vesicular stomatitis virus (VSV).
METHODS
METHODS
Vero cells were treated with different concentrations of TAM for 24 h and then infected with VSV. Additionally, C57BL/6 mice were pretreated with 4 mg TAM, one day and three days before infection with VSV.
Identifiants
pubmed: 31547012
pii: ph12040142
doi: 10.3390/ph12040142
pmc: PMC6958322
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : RTG1949
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer. 2003 May 1;97(9 Suppl):2363-73
pubmed: 12712458
Br J Cancer. 2009 Sep 15;101(6):875-8
pubmed: 19672259
Neuroimmunomodulation. 2000;7(2):68-76
pubmed: 10686515
ACS Infect Dis. 2015 Jul 10;1(7):317-26
pubmed: 27622822
Pediatr Blood Cancer. 2013 Jul;60(7):1108-12
pubmed: 23281268
Curr Med Chem. 2009;16(24):3076-80
pubmed: 19689284
Mol Cell Biochem. 1997 Feb;167(1-2):169-77
pubmed: 9059994
J Biol Chem. 2007 Nov 9;282(45):32765-72
pubmed: 17704057
Curr Med Chem Anticancer Agents. 2004 Nov;4(6):491-508
pubmed: 15579015
Oncol Rev. 2012 Oct 04;6(2):e15
pubmed: 25992213
Eur J Immunol. 2006 Aug;36(8):2094-105
pubmed: 16810635
Clin Cancer Res. 2018 Jul 15;24(14):3397-3408
pubmed: 29661777
Lancet. 1998 May 16;351(9114):1451-67
pubmed: 9605801
Int J Cancer. 1998 Sep 11;77(6):928-32
pubmed: 9714066
Biomedicines. 2017 Feb 10;5(1):
pubmed: 28536351
Viruses. 2018 Feb 23;10(2):
pubmed: 29473868
Clin Cancer Res. 2006 Sep 1;12(17):5010-3
pubmed: 16951214
Hum Vaccin Immunother. 2018;14(9):2107-2113
pubmed: 29757706
J Clin Oncol. 2012 Apr 20;30(12):1268-73
pubmed: 22393101
Blood. 1990 Feb 1;75(3):696-703
pubmed: 2297571
Antibiot Khimioter. 2009;54(7-8):41-9
pubmed: 20201403
Cancer Immunol Immunother. 1993 Aug;37(3):209-12
pubmed: 8334683
Bioinformation. 2016 Jun 15;12(3):135-139
pubmed: 28149048
Nat Med. 1996 Apr;2(4):381-5
pubmed: 8597938
Eur J Immunol. 2016 Feb;46(2):372-80
pubmed: 26507703
Eur J Med Chem. 2018 Jan 1;143:515-531
pubmed: 29207335
Biochem Biophys Res Commun. 2014 Apr 18;446(4):990-6
pubmed: 24657267
Microbes Infect. 2013 Jan;15(1):45-55
pubmed: 23103222
mBio. 2018 Dec 18;9(6):
pubmed: 30563895
Sci Transl Med. 2013 Jun 19;5(190):190ra79
pubmed: 23785035
N Engl J Med. 1989 Feb 23;320(8):479-84
pubmed: 2644532
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
Maturitas. 2011 Dec;70(4):315-21
pubmed: 21982237
Neuro Oncol. 2006 Jan;8(1):47-52
pubmed: 16443947
J Adv Pract Oncol. 2018 Jan-Feb;9(1):78-83
pubmed: 30564470
Biol Pharm Bull. 2012;35(8):1320-7
pubmed: 22863932